Shots:

• The companies signed a multi-year- multifaceted collaboration to develop novel Ab to treat & prevent various diseases including oncology and immunology
• The collaboration leverages H2L2 Harbour Mice platform to generate mAb against SARS CoV 2 – COVID-19 and allow HBM to access Mount Sinai’s research-driven from its clinical practices
• The collaboration demonstrated HBM’s dedication to develop novel therapies and bolster fast-track research. The mAb to be developed in the collaboration have the potential to prevent the spreading of virus by blocking infection of cells

Click here ­to­ read full press release/ article | Ref: Buisnesswire | Image: HBM